Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Work In Process (2023 - 2025)

Cytosorbents (CTSO) has disclosed Work In Process for 3 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Work In Process changed N/A year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Sep 2025, changed N/A, and an annual FY2024 reading of $503000.0, down 40.04% over the prior year.
  • Work In Process was $1.1 million for Q3 2025 at Cytosorbents, up from $782000.0 in the prior quarter.
  • Across five years, Work In Process topped out at $1.1 million in Q3 2025 and bottomed at $503000.0 in Q4 2024.
  • Average Work In Process over 3 years is $775085.4, with a median of $782000.0 recorded in 2025.
  • Peak annual rise in Work In Process hit 40.04% in 2024, while the deepest fall reached 40.04% in 2024.
  • Year by year, Work In Process stood at $838871.0 in 2023, then plummeted by 40.04% to $503000.0 in 2024, then skyrocketed by 124.65% to $1.1 million in 2025.
  • Business Quant data shows Work In Process for CTSO at $1.1 million in Q3 2025, $782000.0 in Q2 2025, and $621556.0 in Q1 2025.